KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s712, 2025. DOI: 10.25251/t4cqj323. Disponível em: https://skin.dermsquared.com/skin/article/view/3898. Acesso em: 21 apr. 2026.